Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATYR-1923 (Primary)
  • Indications Pulmonary sarcoidosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors aTyr Pharma
  • Most Recent Events

    • 14 Nov 2019 According to an aTyr Pharma media release, the company is on track to report an initial interim data analysis focusing on safety data in December.
    • 10 Jul 2019 According to an aTyr Pharma media release, the company will host a Key Opinion Leader (KOL) call and webcast that will provide a brief overview of the Company's lead program, ATYR1923 which is currently being evaluated in this study on Thursday, July 18th at 2pm Eastern Time/11am Pacific Time.
    • 25 Mar 2019 According to an aTyr Pharma media release, interim results from the study are expected in the fourth quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top